Wanjarkhedkar Pankaj, Sarade Girish, Purandare Bharat, Kelkar Dhananjay
Department of Ayurveda & Integrative Medicine, Deenanath Mangeshkar Hospital & Research Center, Pune, MH, India.
Department of Ayurveda & Integrative Medicine, Deenanath Mangeshkar Hospital & Research Center, Pune, MH, India.
J Ayurveda Integr Med. 2022 Jul-Sep;13(3):100575. doi: 10.1016/j.jaim.2022.100575. Epub 2022 Apr 6.
It has been 18 months now since the world-wide outbreak of COVID 19 (Corona Virus Disease 19) and still the ongoing research is being done for disease specific medicines. During June 2020 to August 2020, an attempt was made to explore if an add-on Ayurveda regimen comprising of and in tablet forms can be prescribed along with standard of care; which has established the clinical evidence that there is advantage of accelerated symptomatic recovery, early discharge from hospital, reducing the duration of hospital stay. After informed consent the patients were followed up over 9 months after discharged from hospital. The purpose of the present extended study was to find the impact of disease even though patients were discharged after appropriate treatment and if there were any late effects in the add-on Ayurveda treatment group after 9 months as it was one of the first few formal studies world-wide; since there was no long term follow up data available. The study concluded that no additional late effects or symptoms or complications which were known in Post COVID phase; were observed in study group who received the add-on Ayurveda regimen as compared to the control group with conventional standard of care.
自新冠病毒病(COVID - 19)在全球爆发至今已有18个月,针对该疾病特效药物的研究仍在进行。在2020年6月至2020年8月期间,有人尝试探究是否可以在标准治疗的基础上,加用由片剂形式的[具体药物名称1]和[具体药物名称2]组成的阿育吠陀疗法;这已确立了临床证据,即该疗法具有加速症状缓解、提前出院、缩短住院时间的优势。在获得知情同意后,患者在出院后接受了9个月的随访。本扩展研究的目的是了解即使患者在接受适当治疗后出院,疾病的影响如何,以及在加用阿育吠陀疗法的治疗组中,9个月后是否存在任何迟发效应,因为这是全球首批正式研究之一;当时尚无长期随访数据。研究得出结论,与接受传统标准治疗的对照组相比,接受加用阿育吠陀疗法的研究组在新冠后阶段未观察到已知的额外迟发效应、症状或并发症。